Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCieloPCLOF -23.08% Days Sales Outstanding is 53.00 as of Dec. 2025, which is 20% below its 10-year median of 66.07. The stock has 5 warning signs investors should review. Among 950 Drug Manufacturers companies, PharmaCielo ranks worse than 51.79% on this metric.
PharmaCielo's average Accounts Receivable for the
three
months ended in Dec. 2025 was $0.26 Mil. PharmaCielo's Revenue for the
three
months ended in Dec. 2025 was $0.44 Mil.
Hence, PharmaCielo's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 53.00.
The historical rank and industry rank for PharmaCielo's Days Sales Outstanding or its related term are showing as below:
PCLOF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.05 Med: 66.07 Max: 328.82
Current: 74.39
During the past 8 years, PharmaCielo's highest Days Sales Outstanding was 328.82. The lowest was 30.05. And the median was 66.07.
PCLOF's Days Sales Outstanding is ranked worse than 51.79% of 950
companies
in the Drug Manufacturers industry
Industry Median: 72.065
vs PCLOF: 74.39
PharmaCielo's Days Sales Outstanding
increased
from Sep. 2024 (35.02) to Dec. 2025 (53.00).
PharmaCielo (OTCPK:PCLOF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
PharmaCielo Days Sales Outstanding Related Terms
PharmaCielo Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for PharmaCielo's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where PharmaCielo's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCielo (PCLOF) has a Days Sales Outstanding of 53.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PharmaCielo and its competitors. This is 20% below median its historical median of 66.07. Over the past decade, PharmaCielo's Days Sales Outstanding has ranged from 30.05 to 328.82. According to the industry distribution chart, PharmaCielo ranks #492 out of 950 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is PharmaCielo's Days Sales Outstanding too high?
PharmaCielo's current Days Sales Outstanding of 53.00 is 20% below median its 10-year median of 66.07. Over the past 10 years, this metric has ranged from a low of 30.05 to a high of 328.82. The Drug Manufacturers industry median Days Sales Outstanding is 72.07. PharmaCielo's value of 53.00 is 26.5% below this industry median. Based on the distribution chart, PharmaCielo ranks #492 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does PharmaCielo's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #492 out of 950 companies for Days Sales Outstanding. This places PharmaCielo in the lower half of its industry. The industry median Days Sales Outstanding is 72.07. PharmaCielo's value of 53.00 is 26.5% below this benchmark. Historically, PharmaCielo's own Days Sales Outstanding has ranged from 30.05 to 328.82 over the past decade. While the company's 10-year median is 66.07 vs. the industry median of 72.07, PharmaCielo has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current Days Sales Outstanding of 53.00 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current Days Sales Outstanding is 53.00, which is 20% below median its own 10-year median of 66.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.22, compared to a current price of $0.04 — trading 81.4% below its estimated fair value. The current Days Sales Outstanding is 53.00, which is 20% below median its 10-year median of 66.07 and 26.5% below the Drug Manufacturers industry median of 72.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Days Sales Outstanding is 53.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 
